This study evaluates the duration of intraocular pressure (IOP)-lowering effect and safety of as needed administrations of Bimatoprost sustained release (SR) in participants with open-angle glaucoma (OAG) or ocular hypertension (OHT) who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
515
Study Eye: Cycles 1 - 3 administrations through the PRN treatment period. Fellow Eye: Standard of care or Bimatoprost SR.
Retreatment or rescue administered for IOP
Treatment modality determined by investigator.
Time frame: Up to 48 months
Number of patients experiencing a treatment emergent adverse event
The number of patients who experienced one or more TEAE during the 48 month treatment period.
Time frame: Baseline up to 48 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Horizon Eye Specialists & Lasik Centers /ID# 235240
Sun City, Arizona, United States
Atlantis Eye Care /ID# 235530
Huntington Beach, California, United States
Lakeside Vision Center /ID# 234970
Irvine, California, United States
Global Research Foundation /ID# 237350
Los Angeles, California, United States
The Eye Research Foundation /ID# 234521
Newport Beach, California, United States
Byers Eye Institute Stanford /ID# 235544
Palo Alto, California, United States
Foothill Eye Institute /ID# 235640
Pasadena, California, United States
Connecticut Eye Consultants P.C. /ID# 234981
Danbury, Connecticut, United States
Advanced Research, LLC /ID# 236045
Deerfield Beach, Florida, United States
Segal Drug Trials, Inc /ID# 235784
Delray Beach, Florida, United States
...and 98 more locations